Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fei Li
Observed names:
F Li,
F. Li
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Pudong Medical Center
Observed institutions:
Kanazawa University,
Shanghai Medical College of Fudan University,
Fudan University,
NYU Langone Health,
Pudong Medical Center,
NYU Langone’s Laura and Isaac Perlmutter Cancer Center,
Cancer Research Institute of Kanazawa University,
New York University
show all 8
ORCID:
0000-0002-1973-6611
Observed ORCID:
0000-0002-1973-6611
OpenAlex ID:
A5037088521
H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression
2018
·
S. P. Rowbotham
, F. Li
, et al.
·
Nature Communications
·
86
PDF
The RB–IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity
2017
·
S Kitajima
, A Yoshida
, et al.
·
Oncogene
·
56
EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
·
Cancer Research Communications
·
38
PDF
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
2023
·
Zhen Qin
, Meiting Yue
, et al.
·
The Journal of Experimental Medicine
·
34
PDF
PIM1 enhances insulin secretion and inhibits ferroptosis of high glucose-induced pancreatic β-cells through strengthening PINK1/Parkin-mediated mitophagy via inactivating JNK/p38 signaling pathway
2025
·
Bingjie Fan
, Lili Yin
, et al.
·
Tissue and Cell
·
10
Data from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
·
1
cGAS-STING activation promotes abdominal aortic aneurysm formation in mice and humans: Therapeutic potential of inhibition
2026
·
Pengcheng Du
, Xiaochen Ma
, et al.
·
Biochemical Pharmacology
Data from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
Figure S2 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S1 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S5 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S3 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S6 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S7 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Table S3 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
Figure S4 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Table S2 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
Table S1 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
·
Cancer Research
FIGURE 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
Supplementary Figure 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
Supplementary Figure 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
PDF
Supplementary Table 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
FIGURE 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
FIGURE 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
2024
·
Tanner J. DuCote
, Xiulong Song
, et al.
Show more works
View as search
Works count:
39
Citation count:
225
H-index:
5
I10-index:
5
Year
Topic
Type